Condition: Breast Cancer · TNBC - Triple-Negative Breast Cancer · HER2-negative Breast Cancer · Sponsor: Processa Pharmaceuticals
This is an adaptive Phase 2, open-label, randomized, multi-center study evaluating up to 2 regimens of PCS6422 with capecitabine (Cap) vs. standard dose of Cap alone in patients with advanced or metastatic breast cancer. The goal of the study is to assess the efficacy and safety of PCS6422 + Cap as a treatment option for patients with advanced or metastatic breast cancer who are not eligible for anthracycline- or taxane-containing therapies, or other available therapies, including PD-1 or PARP inhibitors.
This description comes directly from the study's public registry record.
Sian Bigora, PharmD · 410-693-6844 · sbigora@processapharmaceuticals.com
Always discuss trial participation with your own doctor first.
| Arizona Oncology Associates | Tucson, Arizona, United States | Recruiting |
| Valkyrie Clinical Trials | Los Angeles, California, United States | Recruiting |
| FOMAT Medical Research | Oxnard, California, United States | Recruiting |
| AP Medical Research | Miami, Florida, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Northwest Cancer Center | Dyer, Indiana, United States | Recruiting |
| University of Maryland Medical Center (UMMC) | Baltimore, Maryland, United States | Recruiting |
| Rutgers Cancer Institute of New Jersey | New Brunswick, New Jersey, United States | Recruiting |
| Clinical Research Alliance | Westbury, New York, United States | Recruiting |
| Gabrail Cancer Center Research | Canton, Ohio, United States | Recruiting |
| SCRI Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| Texas Oncology PA (Austin) | Austin, Texas, United States | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06568692